The acquisition expands Advanced Health Media’s (AHM) product and service offerings, which optimize the interactions of pharmaceutical sales and marketing professionals with healthcare professionals, improve the co-ordination of marketing activities, and ensure their proactive compliance with relevant regulatory requirements between pharmaceutical companies and healthcare professionals.
The acquisition will increase AHM’s scale to over $400 million in revenue. In addition to the continued equity support provided by Arlington Capital Partners, debt financing for the transaction was provided by CIT Group, Deutsche Bank and the Bank of New York.
Kevin McMurtry, CEO of AHM, said: “The combination of Advanced Health Media and Embryon will provide the pharmaceutical industry with cross-domain skills in medical communications and logistics that will enable our clients to improve the way they interact with physicians and other healthcare professionals, maintain compliance with regulatory requirements, respond more quickly and tailor their solutions to their customer’s needs.”